Emmanuel S Antonarakis MDProfessor of Oncology and Urology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Dr Antonarakis is a Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He graduated from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. In 2010, he joined the Johns Hopkins faculty as an attending physician and translational researcher. Dr Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies (cancers of the bladder, kidney and testis).
His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 marker. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 140 peer-reviewed articles, and several book chapters.
DisclosuresDr. Antonarakis reports no disclosures.
Recent Contributions to PracticeUpdate:
- Apalutamide and Overall Survival in Prostate Cancer
- Clinical Utility of the Nuclear-Localized AR-V7 Biomarker in CTCs in Improving Treatment Choice in Castration-Resistant Prostate Cancer
- Enzalutamide Decreases Risk of Metastasis and Death in Men With Nonmetastatic CRPC
- Enzalutamide Outperforms Abiraterone in Advanced Castration-Resistant Prostate Cancer